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Summary
Antibody-mediated encephalitis has been discussed as one
possible cause for isolated psychotic syndromes. Mostly based
on serum samples, findings have been controversial. We present
the results of a retrospective study of 124 clinically diagnosed
psychotic patients without documented relevant neurological
symptoms. All were tested for different antineuronal antibodies
in cerebrospinal fluid (CSF) while 81 received serum testing.
Antineuronal antibodies in CSF were negative across the sample.
3.7% showed low positive serum antibodies. Our findings
highlight the importance of a deeper discussion about the rele-
vance of low positive serum antibodies without concurrent
findings in CSF or clinical signs for autoimmune encephalitis.
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Usually patients with autoimmune encephalitis develop overt neuro-
logic symptoms.1 However, autoimmune encephalitis can also lead to
severe psychiatric symptoms, such as psychosis, mania, and cognitive
impairment. Interestingly, encephalitis caused by IgG-type antibodies
to the NR1 subunit of theN-methyl-D-aspartate-receptor (NMDAR)
may present exclusively with psychotic symptoms,2 but other auto-
antibodies (e.g. anti-Contactin-associated protein-2 (CASPR2) and
anti-Leucine-rich glioma inactivated 1 protein (LGI1)) have also
been linked to psychotic syndromes.3,4 These observations have led
to the hypothesis that autoimmune encephalitis may be the
primary aetiology in a currently unidentified subgroup of patients
with psychotic disorders. Because autoimmune encephalitis can be
treated with immunosuppressants and its outcome depends on the
time lag to treatment,1 prompt recognition of this cause of psychosis
may have important clinical implications. Although findings to date
have been heterogeneous, the prevalence of pathogenic antineuronal
antibodies is low in blood samples of patients with psychotic disor-
ders.3 In rare cases where neuronal antibodies are detected, the
titres are usually low, and similar titres may also be found in patients
with other neuropsychiatric syndromes or even in healthy people.3,4
However, pathogenic neuronal autoantibodies can be negative in
serum but positive in cerebrospinal fluid (CSF) in patients with auto-
immune encephalitis, especially in patients with better outcomes.5
Analysing CSF may therefore increase the likelihood of detecting
patients with isolated psychosis and presence of pathogenic neuronal
autoantibodies. To the best of our knowledge, only one retrospective
study examined the presence of different neuronal autoantibodies in
CSF of 142 patients with psychotic disorders (125 had surface anti-
body testing), showing positive results in nine patients (four patients
with antibodies against surface and five patients with antibodies
against intracellular antigens).6 However, titres were not reported
and five out of nine patients with positive titres had significant neuro-
logical abnormalities. Here, we present the prevalence of neuronal
antibodies in serum and CSF of patients with a first or recurrent
episode of psychosis without major neurological symptoms that
could indicate an underlying autoimmune encephalitis.7
Methods
We report a naturalistic cohort of 124 patients with schizophrenia
spectrum disorders (first episode and recurrent course) who
underwent a lumbar puncture and were tested for different anti-
neuronal antibodies in CSF and serum as part of the clinical
routine in the Department of Psychiatry and Psychotherapy at the
Klinikum der Universität München between July 2012 and May
2017. Medical data were manually extracted from the electronic
clinical documentation system and retrospectively analysed for
the presence of antineuronal antibodies as well as abnormalities in
routine CSF parameters (white blood cell count, protein levels, oli-
goclonal bands [OCBs] and albumin quotient). We included
patients with documented ICD-10 diagnoses of schizophrenia spec-
trum disorders and excluded patients with a diagnosis of organic
psychotic disorders (F06.0/F06.1/F06.2), drug-induced psychotic
disorder (F1X.5) or clinical signs that could indicate the presence
of an underlying autoimmune encephalitis7 (e.g. seizures, move-
ment disorders, autonomic instability), based on thorough screen-
ing of all available data on clinical and physical examination. We
were able to detect a total of 332 patients with lumbar puncture.
Of these, 124 patients were tested for CSF neuronal antibodies, a
decision made by the treating physicians according to best clinical
judgement. The offer to carry out a lumbar puncture is usually
made in every patient with a first episode and to patients with a
recurrent disease course who had not previously received a lumbar
puncture. The CSF samples were analysed in the laboratory of
our hospital by a cell-based assay from EUROIMMUN (Lübeck,
Germany) for autoimmune encephalitis (antibodies tested: NMDAR
[n = 119], α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
receptor-1 (AMPAR-1) [n = 114], α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor-2 (AMPAR-2) ([n = 114], CASPR2
[n = 111], LGI1 [n = 110] and γ-amino-butyric acid receptor
B1/B2 [n = 112]) and a paraneoplastic neurological syndrome panel
from ravo Diagnostika (Freiburg, Germany) (antibodies tested:
Amphiphysin [n = 93], Yo [n = 59], HuD [n = 94], Ri [n = 94],
CV2 [n = 93], Ma1 [n = 93] and Ma2 [n = 93]). In ten patients,
analyses were performed with the EUROIMMUN assay elsewhere
(Clinical Immunological Laboratory, Lübeck, Germany). Serum
results were available only for 81 patients. The power was at least
95% to detect one or more positive anti-NMDAR CSF titres for
any true rate for positive CSF titres of r0≥ 2.5%. However, as we
detected no positive CSF titres, with a probability of only P < 5%,
we have r0≥ 2.5%. For anti-Yo titres, we had at least 95% power to
detect at least one positive CSF titre for any true rate of r0≥ 5.0%.
Again, we had no positive CSF titres, and therefore with P < 5%
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the true rate of positive CSF titres is r0≥ 5.0%. Approval for this
retrospective analysis was obtained from the Ethikkommission
bei der Medizinischen Fakultät der Ludwig-Maximilians-Universität
München, the approval number for this study is 463-16.
Results
Table 1 outlines the descriptive statistics. None of the 124 patients
with CSF autoantibody analyses showed positive results in any of
the tested antibodies. Three out of 81 patients (3.7%; one female;
mean age, 36 ± 27.78 years) did have low-titre neuronal antibodies
in serum (CASPR-2 antibodies: 1:10; CASPR-2 antibodies: 1:50;
Yo antibodies: low band intensity). All three patients had ≤1 cell/
μl in CSF and unspecific white matter lesions, whereas only one
of these three had positive intrathecal OCBs. Overall, 18 (14.6%)
patients showed intrathecal OCBs and 6 (4.8%) patients showed
pleocytosis within a range of 6–14 cells/μl. None of the patients
showed major abnormalities on neurological examination suggest-
ive of autoimmune encephalitis.
Discussion
In our cohort of patients with schizophrenia spectrum disorder
with no major neurological abnormalities we were unable to
detect positive CSF titres of any of the commonly tested neuronal
autoantibodies. This seems in contrast with a previous publica-
tion.6 However, in that study three out of four patients with
surface autoantibodies had severe neurological symptoms,6
whereas we retrospectively selected patients with isolated psych-
otic symptoms.
We identified three patients with low-level serum autoantibody
titres of whom only two had antibodies against surface antigens.
This low rate of 3.7% conflicts with some studies, but is in line with
others.3,4,6,8 Reasons for these contradicting results havebeendiscussed
indetail before, but themost important are the selectionof patients and
the method of antibody testing.9 Because we did not find antineuronal
antibodies in the CSF of these three patients, we assume that these low-
level serum antibodies do not play a causal role in their psychotic dis-
orders. This is in line with the observation that first-episode patients
with positive serum autoantibodies against different surface antigens
did not show a poorer outcome compared with seronegative patients
and did not develop encephalitis during a 6-month follow-up period.4
Interestingly, 14.6% of our patients showed intrathecal OCBs
and 4.6% showed a mild pleocytosis, which is comparable with pre-
vious reports,10 but significantly below the rates reported for full-
blown autoimmune encephalitis.11 These findings may point to a
possible not yet fully understood central nervous system inflamma-
tory or immune process in schizophrenia.10
The limitations of our study are its retrospective and open design,
the use of a single-screening method and the lack of a control group
and longitudinal data. Because of the retrospective nature of our study
we had to rely upon the documented physical examinations and may
havemissed less overt neurological signs or subtle autonomic instabil-
ity. In addition, we cannot determine how many patients rejected a
lumbar puncture. Moreover, as we only included patients with docu-
mented F2X diagnoses, we may have missed patients with isolated
psychiatric symptoms2 who received a different ICD-10 diagnosis.
To address this, we also analysed all patients with primary or second-
ary diagnoses of organic psychoses (F06.0/F06.1/F06.2) or encephal-
itis (G04/G05) and did not find any isolated psychotic syndrome with
positive CSF autoimmune antibodies. Finally, there is ongoing debate
about the sensitivity of the EUROIMMUN assay.9
In conclusion, our findings highlight the need for a balanced dis-
cussion about the relevance of low-level serum antibody titres in
patients with psychotic disorders withoutmajor clinical signs of auto-
immune encephalitis. They do not invalidate the often urgent clinical
need to offer comprehensive serum and CSF analyses to all patients
presenting with either a combination of psychotic symptoms and
major neurological signs or a combination of psychotic symptoms
and clinical criteria for autoimmune encephalitis.7
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Table 1 Descriptive data of our cohort
Cohort Description (N = 124) N
Epidemiologic and demographic information
Gender (female/male) 60/64
Average age at the time of the lumbar puncture
(years ± s.d.)
36.85 ± 15.29
Positive family history for psychiatric illnesses
(n = 119)
47.1%
Prevalence of any neurological diagnosis 3.2%
Illegal substance misuse (n = 123) 19.5%
Alcohol misuse (n = 122) 26.2%
Information about psychiatric illness
Duration of illness at the time of lumbar puncture
(months ± s.d.) (n = 109)
61.58 ± 97.99
First episode at the time of lumbar puncture (n = 122) 44.3%
Recurrent psychotic episode (n = 122) 55.7%
Documented treatment with clozapine 24.2%
Cerebrospinal fluid basic panel
White blood cell count (cells/μl ± s.d.) 1.58 ± 2.04
Prevalence of pleocytosis (>5 cells/μl) 4.8%
Protein level (mg/dl ± s.d.) 40.01 ± 16.72
Albumin quotient (±s.d.) (n = 123) 5.98 ± 2.98
Prevalence of oligoclonal bands (n = 123) 41.5%
Intrathecal oligoclonal bands 14.6%
Mirrored 26.8%
Diagnosis
Schizophrenia (ICD-10: F20) 62.1%
Schizotypal disorder (ICD-10: F21) 3.2%
Persistent delusional disorders (ICD-10: F22) 5.6%
Acute and transient psychotic disorders (ICD-10: F23) 13.7%
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